Cempra (CEMP) Receives Price Target

Cempra (CEMP) : The highest level Cempra (CEMP) is projected to reach is $51 for the short term and the lowest estimate is at $25. The consolidated price target from 9 rating analysts who initiate coverage on the stock is $39.22 and the possibility the share price can swing is $7.6.

Cempra (CEMP) has an average broker rating of 1.25, which is interpreted as a Strong Buy, as rated by 10 equity analysts. Nonetheless, 8 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. 1 other analysts advise a Buy. Nevertheless, the majority of 1 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.


Also, Brokerage firm Jefferies maintains its rating on Cempra (NASDAQ:CEMP). As per the latest information, the brokerage house lowers the price target to $40 per share from a prior target of $42. The shares have been rated Buy. The rating by the firm was issued on August 2, 2016.

Cempra (NASDAQ:CEMP): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $21.99 and $21.72 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $22.50. The buying momentum continued till the end and the stock did not give up its gains. It closed at $22.29, notching a gain of 1.60% for the day. The total traded volume was 737,312 . The stock had closed at $21.94 on the previous day.

Cempra Inc. is a clinical-stage pharmaceutical company focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. The Companys lead product, solithromycin, is being developed in oral capsules, intravenous, or IV, and suspension formulations, initially for the treatment of community acquired bacterial pneumonia, or CABP, an infection of the respiratory tract. The Companys second product is Taksta, an antibiotic known as fusidic acid, that has been used for decades outside the United States, including Western Europe, but , which has never been approved in the United States. The Company is developing Taksta in the United States as an oral treatment of refractory bone and joint infections caused by staphylococci.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.